Therapeutic drug monitoring guided fluconazole therapy in a patient with cholangitis sepsis.

IF 1.7 4区 医学 Q3 PHARMACOLOGY & PHARMACY Personalized medicine Pub Date : 2022-01-01 Epub Date: 2021-11-08 DOI:10.2217/pme-2021-0010
Jana Duricova, Pavla Jadrnickova, Hana Brozmanova, Ivana Kacirova
{"title":"Therapeutic drug monitoring guided fluconazole therapy in a patient with cholangitis sepsis.","authors":"Jana Duricova,&nbsp;Pavla Jadrnickova,&nbsp;Hana Brozmanova,&nbsp;Ivana Kacirova","doi":"10.2217/pme-2021-0010","DOIUrl":null,"url":null,"abstract":"<p><p><i>Candida</i> and other fungal species play an increasing role in nosocomial infections, including cholangitis and cholangiosepsis. Early diagnosis and prompt treatment are essential in successful patient outcomes. Fluconazole is an antifungal of choice in fluconazole-sensitive <i>Candida</i> infections. Little information is known about the fluconazole biliary excretion. Decreased tissue penetration may be one of the possible causes of treatment failure. Due to favorable pharmacokinetics, therapeutic drug monitoring of this antifungal has not been recommended routinely. In the presented case we report the successful therapeutic drug monitoring-guided fluconazole treatment in a patient with cholangitis and cholangiosepsis caused by fluconazole-sensitive <i>Candida</i> spp.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"19 1","pages":"9-14"},"PeriodicalIF":1.7000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Personalized medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pme-2021-0010","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/11/8 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 1

Abstract

Candida and other fungal species play an increasing role in nosocomial infections, including cholangitis and cholangiosepsis. Early diagnosis and prompt treatment are essential in successful patient outcomes. Fluconazole is an antifungal of choice in fluconazole-sensitive Candida infections. Little information is known about the fluconazole biliary excretion. Decreased tissue penetration may be one of the possible causes of treatment failure. Due to favorable pharmacokinetics, therapeutic drug monitoring of this antifungal has not been recommended routinely. In the presented case we report the successful therapeutic drug monitoring-guided fluconazole treatment in a patient with cholangitis and cholangiosepsis caused by fluconazole-sensitive Candida spp.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
治疗药物监测指导氟康唑治疗胆管炎脓毒症1例。
念珠菌和其他真菌种类在医院感染中起着越来越重要的作用,包括胆管炎和胆管败血症。早期诊断和及时治疗对患者的成功预后至关重要。氟康唑是氟康唑敏感念珠菌感染的首选抗真菌药物。关于氟康唑胆排泄的信息知之甚少。组织穿透减少可能是治疗失败的可能原因之一。由于良好的药代动力学,这种抗真菌药物的治疗监测尚未被常规推荐。在本病例中,我们报告了治疗药物监测引导氟康唑治疗由氟康唑敏感念珠菌引起的胆管炎和胆管败血症患者的成功。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Personalized medicine
Personalized medicine 医学-药学
CiteScore
3.30
自引率
4.30%
发文量
49
审稿时长
6-12 weeks
期刊介绍: Personalized Medicine (ISSN 1741-0541) translates recent genomic, genetic and proteomic advances into the clinical context. The journal provides an integrated forum for all players involved - academic and clinical researchers, pharmaceutical companies, regulatory authorities, healthcare management organizations, patient organizations and others in the healthcare community. Personalized Medicine assists these parties to shape thefuture of medicine by providing a platform for expert commentary and analysis. The journal addresses scientific, commercial and policy issues in the field of precision medicine and includes news and views, current awareness regarding new biomarkers, concise commentary and analysis, reports from the conference circuit and full review articles.
期刊最新文献
Challenges and opportunities in building a health economic framework for personalized medicine in oncology. Developing and validating noninvasive prenatal testing for de novo autosomal dominant monogenic diseases in Vietnam. Budget impact and transferability of cost-effectiveness of DPYD testing in metastatic breast cancer in three health systems. Financial incentives to promote personalized medicine in Europe: an overview and guidance for implementation. Cost-effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1